Immunotherapy for Breast Cancer
Updated: 1 hour ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: September 2026
TL;DR: Immunotherapy treats breast cancer by training the body's immune system to identify and destroy cancerous cells. It is currently approved primarily for high-risk early-stage and metastatic triple-negative breast cancer, using intravenous medications such as pembrolizumab or dostarlimab. While these treatments offer improved survival rates, they can cause side effects ranging from fatigue to serious autoimmune reactions.
Quick Answer: What Is Immunotherapy for Breast Cancer?
Immunotherapy for breast cancer is a specialized treatment that boosts the body's natural defenses to attack cancer cells. It is currently used for high-risk and metastatic triple-negative breast cancer, either as an active treatment that focuses on specific antigens or a passive one that enhances existing immune tools. Administered by IV every three to six weeks, it can significantly improve cure rates and long-term survival for eligible patients, while being monitored for common side effects such as fatigue or thyroid issues.
Breast cancer immunotherapy represents a significant advancement in oncology, particularly for types of the disease that have historically been difficult to treat. By leveraging the body's own immune system, this therapy provides a targeted approach that can work alongside traditional treatments like surgery and chemotherapy.
What Are the Types of Immunotherapy?
Immunotherapy works by either training the immune system to recognize cancer cells more effectively or by providing the body with lab-made tools to enhance its natural response. It is classified into two primary categories based on how it interacts with the immune system.
Active immunotherapy: focuses the immune system on specific antigens found on cancer cells. The goal is to train the body to proactively find and kill cancer cells.
Passive immunotherapy: uses lab-made drugs to improve existing immune system tools. The goal is to enhance the body's current cancer-fighting capabilities.
Which Immunotherapy Medications Are Approved for Breast Cancer?
The regulatory landscape for breast cancer immunotherapy is evolving, with specific drugs approved for particular stages and types of the disease. Currently, these treatments are most frequently applied to triple-negative breast cancer (TNBC), which lacks the receptors targeted by hormone-based therapies.
Pembrolizumab: blocks a specific protein on cancer cells that allows them to hide from the immune system. It is used for both high-risk early-stage TNBC, often before and after surgery, and metastatic cases that carry specific tumor markers.
Dostarlimab: specifically approved for metastatic breast cancer that has continued to spread during or after other treatments, provided the tumor carries a specific genetic biomarker.
How Is Immunotherapy Given, and for How Long?
Receiving immunotherapy is a clinical process that requires regular visits to a healthcare facility. The medication is delivered directly into the bloodstream to ensure optimal distribution throughout the body.
Method: intravenous (IV) line injection into the veins.
Frequency: typically every three to six weeks.
Duration: can last from several months up to two years, depending on the case.
What Are the Side Effects and Risks of Immunotherapy?
While immunotherapy is designed to target cancer cells, it can sometimes cause the immune system to become overactive or affect healthy tissues. Patients are closely monitored throughout their treatment course to manage these reactions.
Common side effects often include persistent fatigue, skin rashes, diarrhea, and issues with the thyroid gland. More serious but less frequent risks include infusion reactions, characterized by fever, chills, or breathing difficulties, and autoimmune reactions, in which the immune system begins to attack healthy organs.
What Is the Outlook After Immunotherapy?
The success of immunotherapy is measured by improved cure rates and extended survival, particularly for patients with triple-negative breast cancer. Ongoing research is evaluating these treatments for other types of the disease, including HER2-positive and ER-positive breast cancers.
Conclusion
Immunotherapy has emerged as a vital tool in the fight against breast cancer, offering new hope for those with high-risk and metastatic conditions. By training the body's own defenses, it provides a powerful supplement to traditional surgical and chemical interventions. As clinical trials continue to expand, the potential for these treatments to help a broader range of patients remains a significant focus of modern oncology.
Next Steps
Patients diagnosed with high-risk or metastatic triple-negative breast cancer should consult with their oncology team to determine whether they are candidates for approved immunotherapy drugs. Discussing the potential for clinical trials can also provide access to emerging treatments that may further improve long-term outcomes.
Frequently Asked Questions (FAQ)
What is immunotherapy for breast cancer?
It is a treatment that boosts your immune system to help it find and kill breast cancer cells.
Who is a candidate for this treatment?
Currently, it is primarily used for high-risk early-stage and metastatic triple-negative breast cancer.
How does active immunotherapy differ from passive immunotherapy?
Active immunotherapy trains the immune system to find specific antigens, while passive immunotherapy enhances existing immune tools.
What is triple-negative breast cancer?
It is a type of breast cancer that lacks three common receptors, making it a primary target for immunotherapy.
How is the medication administered?
It is delivered through an intravenous (IV) line into your veins.
How often will I receive treatments?
Most patients receive a dose every three to six weeks.
How long does the overall treatment last?
It can range from a few months up to two years, depending on individual needs.
What are the most common side effects?
Fatigue, skin rashes, diarrhea, and thyroid issues are frequently reported.
What is an infusion reaction?
It is a serious side effect during administration that can cause fever, chills, or breathing trouble.
Can immunotherapy cause autoimmune issues?
Yes, it can sometimes cause the immune system to attack healthy parts of the body.
Does immunotherapy work better than chemotherapy alone?
Studies show that combining certain immunotherapies with chemotherapy can lead to longer survival.
Is immunotherapy used for HER2-positive breast cancer?
It is currently being evaluated in clinical trials for HER2-positive and ER-positive types.
What is the role of pembrolizumab?
It blocks a protein that helps cancer cells hide from the immune system.
What are biomarkers in this context?
Biomarkers are specific tumor markers that indicate whether a patient's cancer is likely to respond to a certain drug.
What should I do if I experience side effects?
Contact your healthcare team immediately to manage any reactions or symptoms.
References
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare professional regarding any medical condition or treatment.
Comments